PD-L1 Expression in Endocervical Adenocarcinoma: Correlation With Patterns of Tumor Invasion, CD8+ Tumor-infiltrating Lymphocytes, and Clinical Outcomes.

Autor:	Rivera-Colon G; Departments of Pathology.; Department of Pathology, Parkland Hospital, Dallas, TX., Chen H; Departments of Pathology.; Department of Pathology, Parkland Hospital, Dallas, TX., Molberg K; Departments of Pathology.; Department of Pathology, Parkland Hospital, Dallas, TX., Niu S; Departments of Pathology.; Department of Pathology, Parkland Hospital, Dallas, TX., Strickland AL; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL., Castrillon DH; Departments of Pathology.; Obstetrics and Gynecology.; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center.; Department of Pathology, Parkland Hospital, Dallas, TX., Carrick K; Departments of Pathology.; Department of Pathology, Parkland Hospital, Dallas, TX., Gwin K; Departments of Pathology.; Department of Pathology, Parkland Hospital, Dallas, TX., Lea J; Obstetrics and Gynecology.; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center., Zheng W; Departments of Pathology.; Obstetrics and Gynecology.; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center.; Department of Pathology, Parkland Hospital, Dallas, TX., Lucas E; Departments of Pathology.; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center.; Department of Pathology, Parkland Hospital, Dallas, TX.
Jazyk:	angličtina
Zdroj:	The American journal of surgical pathology [Am J Surg Pathol] 2021 Jun 01; Vol. 45 (6), pp. 742-752.
DOI:	10.1097/PAS.0000000000001633
Abstrakt:	Programmed death-1 ligand (PD-L1) expression has been used as a predictive marker for response to immune checkpoint inhibitors and has been reported to have prognostic value. Its prevalence and significance in endocervical adenocarcinoma (ECA) remain underinvestigated. We evaluated PD-L1 expression and CD8+ tumor-infiltrating lymphocyte density in whole tissue sections of 89 ECAs. PD-L1 expression was observed in 68% of ECAs by combined positive score (CPS, cutoff 1) and 29% of ECAs by tumor proportion score (TPS, cutoff 1%). Using CPS, PD-L1 expression was seen in 11%, 78%, and 72% of pattern A, B, and C tumors, respectively, with significantly higher expression in tumors with destructive-type invasion (B and C) (P=0.001 [A vs. B], 0.0006 [A vs. C], 0.0002 [A vs. B+C]). Using TPS, no significant difference in PD-L1 expression was seen between tumors with different invasion patterns (0%, 22%, and 32% in tumors with pattern A, B, and C, respectively; P=0.27 [A vs. B], 0.053 [A vs. C], 0.11 [A vs. B+C]). PD-L1-positive ECAs demonstrated significantly higher CD8+ tumor-infiltrating lymphocyte density (CPS: P=0.028; TPS: P=0.013) and worse progression-free survival when compared with PD-L1-negative ECAs (CPS: hazard ratio [HR]=4.253 vs. 0.235, P=0.025; TPS: HR=4.98 vs. 0.2; P=0.004). When invasion patterns were separately assessed, pattern C tumors similarly showed worse progression-free survival in PD-L1-positive tumors (CPS: HR=6.15 vs. 0.16, P=0.045; TPS: HR=3.78 vs. 0.26, P=0.027). In conclusion, our data show frequent PD-L1 expression in ECA with destructive-type invasion, supporting the role of the PD-1/PD-L1 pathway as a therapeutic target for these tumors. Our data also support PD-L1 as a negative prognostic marker associated with a potentially unfavorable outcome. Competing Interests: Conflicts of Interest and Source of Funding: Partially funded by the UT Southwestern Medical Center, Department of Pathology; intramural research fund of the Department of Pathology, UT Southwestern Medical Center to G.R.-C., Mark and Jane Gibson endowment fund, UT Southwestern Medical Center to W.Z., and Philip O’Bryan Montgomery endowment fund, UT Southwestern Medical Center to K.M. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu